Adding vilobelimab (IFX-1) to standard of care treatment is safe and well-tolerated among patients with ANCA-associated vasculitis (AAV), according to top-line results from the ongoing Phase 2 IXPLORE study. Some participants also showed clinical response and remission, although the study was not designed to assess the statistical significance…
Vilobelimab Safe, Well-tolerated in Phase 2 IXPLORE Study
The likelihood of developing ANCA-associated vasculitis rises significantly among people living near quarries that extract quartz with silica, a data analysis from France reported. Its findings also support silica exposure as a specific environmental risk factor for this disease. …
A committee of the U.S. Food and Drug Administration (FDA) — which provides the agency with non-binding recommendations from independent medical experts — has narrowly supported the approval of avacopan for the treatment of ANCA-associated vasculitis (AAV). In the final segment of a public meeting,…
Activities ranging from sporting wearable art to highlighting “patient heroes” are underway to mark Vasculitis Awareness Month (VAM), set aside each May to call attention to this rare autoimmune disease. International Vasculitis Day is May 15. Awareness and education are crucial to increasing the recognition, diagnosis, understanding, and management of…
A molecule released by platelets — cell fragments in the blood that form clots and stop or prevent bleeding — appears to contribute to the progression of ANCA-associated vasculitis (AAV) by triggering a defense mechanism carried out by white blood cells. Researchers now have identified a key signaling event…
As I was walking around my house today looking at all the accumulated dust bunnies and housework I need to do, I came across my husband’s treasured Kintsugi bowl, and it made me think. In Japan, instead of throwing out broken and battered pottery, the art of Kintsugi is…
Nucala (mepolizumab) is effective and safe in combination with corticosteroids to treat eosinophilic granulomatosis with polyangiitis (EGPA), resulting in decreased disease activity and increased remission rates than standard treatment alone, a small study has found. Patients taking Nucala received…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…
Serious infections occur more frequently in people with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis who have higher disease activity at diagnosis, a real-world, long-term study showed. Moreover, most serious infections occur during the first year after the ANCA vasculitis diagnosis, the study found.
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…
Recent Posts
- Kidney inflammation often worse for children with AAV vs. adults, study finds
- Using the spoon theory to manage my energy with chronic illness
- FDA proposes removing Tavneos from market over data concerns
- Testing iron protein in blood may improve AAV monitoring and care
- Even with ANCA vasculitis, we can be awe-struck by our own bodies